HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Very high dose cyclophosphamide with imidazole carboximide and vincristine sulfate in the treatment of stage IV neuroblastoma.

Abstract
To address the problem of drug dosage as a limiting factor for successful chemotherapy, seven patients with Stage IV neuroblastoma were treated with very high dose cyclophosphamide with imidazole carboximide (DTIC) and vincristine sulfate in conjunction with intensive supportive care. None of the patients experienced a complete response. The major toxicity was myelosuppression, complicated by significant infections. Toxicity was significantly more severe in this study than in similar regimens using these three drugs at conventional doses. Although the number of patients in this study was small and most had received prior therapy, our data do not support the efficacy of very high dose cyclophosphamide in the treatment of Stage IV neuroblastoma.
AuthorsU Srinivasan, D Glaubiger, A S Levine, I T Magrath, P A Pizzo, D G Poplack
JournalAmerican journal of clinical oncology (Am J Clin Oncol) Vol. 8 Issue 3 Pg. 210-4 (Jun 1985) ISSN: 0277-3732 [Print] UNITED STATES
PMID4050739 (Publication Type: Journal Article)
Chemical References
  • Vincristine
  • Dacarbazine
  • Cyclophosphamide
Topics
  • Adolescent
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols (administration & dosage, adverse effects)
  • Brain Neoplasms (drug therapy)
  • Child
  • Child, Preschool
  • Cyclophosphamide (administration & dosage)
  • Dacarbazine (administration & dosage)
  • Drug Administration Schedule
  • Drug Evaluation
  • Female
  • Humans
  • Infant
  • Male
  • Neuroblastoma (drug therapy)
  • Vincristine (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: